These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4028625)

  • 21. Scopolamine for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2004; (3):CD002851. PubMed ID: 15266468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Transdermal scopolamine or droperidol in the prevention of postoperative nausea and vomiting in cholecystectomy patients].
    Schuh R; Tolksdorf W; Hucke H
    Anasth Intensivther Notfallmed; 1987 Dec; 22(6):261-6. PubMed ID: 3326423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double blind comparison of transdermal hyoscine and placebo for the prevention of postoperative nausea.
    Koski EM; Mattila MA; Knapik D; Toivanen T; Ruusukallio H; Andersson P; Freudenthal Y
    Br J Anaesth; 1990 Jan; 64(1):16-20. PubMed ID: 2405893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Transdermal scopolamine to prevent postoperative nausea and vomiting after uterine curettage and termination of pregnancy. A double-blind clinically controlled study with placebo].
    Jespersen TW; Koch J; Anker-Møller E; Spangsberg NL; Johansen UT; Grydehøj P
    Ugeskr Laeger; 1989 May; 151(20):1246-8. PubMed ID: 2660376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal scopolamine for the reduction of postoperative nausea in outpatient ear surgery: a double-blind, randomized study.
    Reinhart DJ; Klein KW; Schroff E
    Anesth Analg; 1994 Aug; 79(2):281-4. PubMed ID: 7639364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Clissold SP; Heel RC
    Drugs; 1985 Mar; 29(3):189-207. PubMed ID: 3886352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia.
    Doyle E; Byers G; McNicol LR; Morton NS
    Br J Anaesth; 1994 Jan; 72(1):72-6. PubMed ID: 8110556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia.
    Harris SN; Sevarino FB; Sinatra RS; Preble L; O'Connor TZ; Silverman DG
    Obstet Gynecol; 1991 Oct; 78(4):673-7. PubMed ID: 1923171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accidental mydriasis from scopolamine patches.
    Rosen NB
    J Am Optom Assoc; 1986 Jul; 57(7):541-2. PubMed ID: 3745760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative transdermal scopolamine does not reduce the level of nausea and frequency of vomiting after laparoscopic cholecystectomy.
    Sohi HS; Heipel J; Inman KJ; Chinnick B; Cunningham DG; Holliday RL; Girotti MJ
    Can J Surg; 1994 Aug; 37(4):307-12. PubMed ID: 8055388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of transdermal scopolamine upon psychological test performance at sea.
    Parrott AC; Jones R
    Eur J Clin Pharmacol; 1985; 28(4):419-23. PubMed ID: 4029247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN; Ezzo DC
    Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on effect of acupoint sticker of TTS-ST93-1 in treating motion sickness].
    Pei J; Yang T; Liu Z
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 Aug; 18(8):464-7. PubMed ID: 11477828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time.
    Howland J; Rohsenow DJ; Minsky S; Snoberg J; Tagerud S; Hunt SK; Almeida A; Greece J; Allensworth-Davies D
    Int J Occup Environ Health; 2008; 14(4):250-6. PubMed ID: 19043911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.